Phase Ib/II trial of lenvatinib plus pembrolizumab in advanced melanoma.

被引：2
|
作者：
Taylor, Matthew H.
Vogelzang, Nicholas J.
Cohn, Allen Lee
Stepan, Daniel E.
Shumaker, Robert Charles
Dutcus, Corina E.
Guo, Matthew
Schmidt, Emmett V.
Rasco, Drew W.
机构：
[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[2] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[3] US Oncol, Rocky Mt Canc Ctr, Denver, CO USA
[4] Eisai Inc, Woodcliff Lake, NJ USA
[5] Merck & Co Inc, Kenilworth, NJ USA
[6] South Texas Accelerated Res Therapeut, San Antonio, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 08期
关键词：
D O I：
10.1200/JCO.2019.37.8_suppl.15
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
15
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Endometrial Carcinoma
    Makker, Vicky
    Rasco, Drew
    Dutcus, Corina
    Stepan, Daniel
    Li, Di
    Schmidt, Emmett
    Shumaker, Robert
    Young, Louise
    Taylor, Matthew
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 152 - 153
  • [2] Phase Ib/II trial of lenvatinib plus pembrolizumab in urothelial cancer.
    Vogelzang, Nicholas J.
    Encarnacion, Carlos A.
    Cohn, Allen Lee
    DiSimone, Christopher
    Rasco, Drew W.
    Richards, Donald A.
    Taylor, Matthew H.
    Dutcus, Corina E.
    Stepan, Daniel E.
    Shumaker, Robert Charles
    Guo, Matthew
    Schmidt, Emmett V.
    Mier, James Walter
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [3] A Phase IB/II Trial of Lenvatinib plus Pembrolizumab in Patients With Renal Cell Carcinoma
    Lee, Chung-Han
    Makker, Vicky
    Rasco, Drew
    Taylor, Matthew
    Dutcus, Corina
    Shumaker, Robert
    Schmidt, Emmett
    Stepan, Daniel E.
    Li, Di
    Young, Louise
    Motzer, Robert
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 153 - 153
  • [4] A phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with advanced melanoma.
    Shaikh, Saba
    Zang, Yan
    Hanmer, Janel
    Wang, Hong
    Lin, Yan
    Davar, Diwakar
    Zarour, Hassane M.
    Kirkwood, John M.
    Najjar, Yana G.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] NeoPlus: A phase II study of neoadjuvant lenvatinib and pembrolizumab in resectable mucosal melanoma.
    Mao, Lili
    Si, Lu
    Dai, Jie
    Bai, Xue
    Li, Caili
    Wei, Xiaoting
    Cui, Chuanliang
    Chi, Zhihong
    Sheng, Xinan
    Tang, Bixia
    Lian, Bin
    Wang, Xuan
    Yan, Xieqiao
    Zhou, Li
    Kong, Yan
    Wu, Xiaowen
    Li, Siming
    Li, Juan
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
    Taylor, Matthew H.
    Lee, Chung-Han
    Makker, Vicky
    Rasco, Drew
    Dutcus, Corina E.
    Wu, Jane
    Stepan, Daniel E.
    Shumaker, Robert C.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (11) : 1154 - +
  • [7] A phase Ib/II trial of lenvatinib plus pembrolizumab in non-small cell lung cancer.
    Brose, Marcia S.
    Vogelzang, Nicholas J.
    DiSimone, Christopher
    Jain, Sharad K.
    Richards, Donald A.
    Encarnacion, Carlos A.
    Rasco, Drew W.
    Shumaker, Robert Charles
    Dutcus, Corina E.
    Stepan, Daniel E.
    Guo, Matthew
    Schmidt, Emmett V.
    Taylor, Matthew H.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [8] A phase Ib/II trial of lenvatinib (LEN) plus pembrolizumab (Pembro) in patients (Pts) with endometrial carcinoma.
    Makker, Vicky
    Rasco, Drew W.
    Dutcus, Corina E.
    Stepan, Daniel E.
    Li, Di
    Schmidt, Emmett V.
    Shumaker, Robert Charles
    Taylor, Matthew H.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [9] Correlative serum biomarker analyses: Lenvatinib (LEN) plus pembrolizumab (PEMBRO) in a phase Ib/II trial in advanced renal cell carcinoma (RCC)
    Lee, C-H.
    Adachi, Y.
    Ikezawa, H.
    Li, S. D.
    Funahashi, Y.
    Minoshima, Y.
    Kubiak, P.
    Perini, R.
    Ren, M.
    Smith, A. D.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2020, 31 : S564 - S565
  • [10] A phase Ib study of napabucasin plus weekly paclitaxel in patients with advanced melanoma.
    Edenfield, William Jeffery
    Becerra, Carlos
    Braiteh, Fadi S.
    Spira, Alexander I.
    Sullivan, Ryan J.
    Panella, Timothy J.
    Li, Wei
    Huang, Janet
    Li, Youzhi
    Flaherty, Keith
    Hitron, Matthew
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345